Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL130746 | 0.78 | — | — | |
| SCHEMBL23790310 | 0.77 | OPRM1 (0.36) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL2292865 | 0.73 | — | — | |
| SCHEMBL2295003 | 0.73 | — | — | |
| SCHEMBL8446741 | 0.72 | OPRM1 (0.32) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL1414825 | 0.71 | OPRM1 (0.36) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL18268918 | 0.71 | OPRM1 (0.36) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL17487284 | 0.71 | OPRM1 (0.36) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL10905967 | 0.71 | — | — | |
| SCHEMBL24517528 | 0.70 | OPRM1 (0.33) | OPRM1OPRD1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0802908-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2001-04-11 | — | — | EP | claimed |
| EP-0883402-A4 | NOVEL CYCLOALKYL SUBSTITUDED IMIDAZOLES | SMITHKLINE BEECHAM CORP (US) | 1999-08-11 | — | — | EP | claimed |
| US-5929076-A | Cycloalkyl substituted imidazoles | SMITHKLINE BEECHAM CORPORATION (US) | 1999-07-27 | — | — | US | claimed |
| EP-0889726-A4 | NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES | SMITHKLINE BEECHAM CORP (US) | 1999-07-21 | — | — | EP | claimed |
| CN-1213305-A | Novel cycloalkyl substituted imidazolium compounds | SMITHKLINE BEECHAM CORP (US) | 1999-04-07 | — | — | CN | claimed |
| EP-0889726-A1 | NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-13 | — | — | EP | claimed |
| EP-0883402-A1 | NOVEL CYCLOALKYL SUBSTITUDED IMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1998-12-16 | — | — | EP | claimed |
| CN-1177959-A | Novel compounds | SMITHKLINE BEECHAM CORP (US) | 1998-04-01 | — | — | CN | claimed |
| EP-0802908-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-10-29 | — | — | EP | claimed |
| WO-1997025048-A1 | NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-17 | — | — | WO | claimed |
| WO-1997025047-A1 | NOVEL CYCLOALKYL SUBSTITUDED IMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-17 | — | — | WO | claimed |
| WO-1996021654-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-07-18 | — | — | WO | claimed |
| US-11040981-B2 | Pyrrolotriazine compounds and methods of inhibiting TAM kinases | SYROS PHARMACEUTICALS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20210147431-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | SYROS PHARMACEUTICALS INC (US) | 2021-05-20 | — | — | US | disclosed |
| CN-112368285-A | Pyrrolotriazine compounds and methods of inhibiting TAM kinase | 希洛斯医药品股份有限公司 | 2021-02-12 | — | — | CN | disclosed |
| US-20200317676-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | SYROS PHARMACEUTICALS, INC. (US) | 2020-10-08 | — | — | US | disclosed |
| EP-3694860-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | Syros Pharmaceuticals, Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| WO-2019074962-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | SYROS PHARMACEUTICALS, INC. (US) | 2019-04-18 | — | — | WO | disclosed |
| CN-102421761-B | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC | 2014-06-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147431-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | PLK2, MAP3K5, CAMKK2 | OPRM1 1558/4885OPRD1 2790/4885OPRK1 747/4885 |
| US-20200317676-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | PLK2, MAP3K5, CAMKK2 | OPRM1 1558/4885OPRD1 2790/4885OPRK1 747/4885 |
| US-11040981-B2 | Pyrrolotriazine compounds and methods of inhibiting TAM kinases | PLK2, MAP3K5, CAMKK2 | OPRM1 1558/4885OPRD1 2790/4885OPRK1 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.